Allos Therapeutics to Present at Upcoming Conferences in November
|
|
|
| Posted
:
Tue, 10 Nov 2009 15:13:35 GMT |
| Author
:
Allos Therapeutics
|
| Category
:
Press Release |
| News Alerts by
Email ( click
here ) |
| Press Release
News |
Home
|
|
|
|
WESTMINSTER, Colo. - (Business Wire) Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics, today announced that management will present at two upcoming conferences: the Lazard Capital Markets 6th Annual Healthcare Conference and the Windhover Therapeutic Area Partnerships event, where the Company’s Pralatrexate for Peripheral T-cell Lymphoma project was named as one of Windhover’s Top 10 interesting oncology projects. Details are as follows: | Event: | | Lazard Capital Markets 6th Annual Healthcare Conference | | Date: | | Tuesday, November 17, 2009 | | Time: | | 3:40 p.m. Eastern Time | | Place: | | The St. Regis Hotel, New York City | | | | | Event: | | Windhover’s Therapeutic Area Partnerships Event | | Date: | | Wednesday, November 18, 2009 | | Time: | | 1:45 p.m. Eastern Time | | Place: | | Westin Copley Place, Boston | There will be a live webcast of the Lazard Capital Markets presentation, which will be accessible through a link posted on the “Investors - Presentations and Events” section of the Company’s website at www.allos.com. The webcast will be available for replay for two weeks. About Allos Therapeutics Allos Therapeutics, Inc. (Nasdaq: ALTH) is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. Allos is currently focused on the development and commercialization of FOLOTYNTM (pralatrexate injection), a folate analogue metabolic inhibitor. FOLOTYN is the first and only drug approved in the U.S. for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Allos is also developing FOLOTYN in other potential indications. Allos retains exclusive worldwide rights to FOLOTYN for all indications. Allos is headquartered in Westminster, CO. For additional information, please visit www.allos.com. Safe Harbor Statement The anticipated presentations will contain forward-looking statements that involve significant risks and uncertainties. Additional information concerning these forward-looking statements and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2009 and in the Company's other periodic reports and filings with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in the presentations. All forward-looking statements are based on information currently available to the Company on the date thereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of these presentations, except as required by law.
Allos Therapeutics
Monique Greer, 720-540-5268
mgreer@allos.com
|
Copyright © 2008
Business Wire. All rights reserved.
|
|
|
|
|
Related
News
Technology a Permanent Resident in Homes According to Milwaukee/NARI Experts
Members of the Milwaukee/NARI Home Improvement Council, Inc., the area’s leading home improvement and remodeling industry resource for more than 48 years, offer suggestions to homeowners of ways to enhance and update the technology in their homes./I/P
P(Vocus) November 21, 2009 --...
Christmas City, Special Events, ‘Spirit Of The Season’ Deals Add To Holiday Cheer In Lehigh Valley
With “The Christmas City” of Bethlehem as the epicenter of activities, Lehigh Valley offers families, couples and groups a wide assortment of unique and memorable holiday attractions. And with affordable “Spirit of the Season” Stay & Celebrate promotional packages ...
U.S. Census Bureau Daily Feature for Nov. 22
WASHINGTON, Nov. 22 /PRNewswire-USNewswire/ -- Following is the daily "Profile America" feature from the U.S. Census Bureau:
(Logo: http://www.newscom.com/cgi-bin/prnh/20090226/CENSUSLOGO)
VA Maryland Health Care System Receives Performance Achievement Carey Award
The VA Maryland Health Care System won the Robert W. Carey Performance Achievement Award for its excellent performance in patient care, patient satisfaction, quality, safety and business practices./I/P
P(Vocus) November 21, 2009 -- At the 18th Annual Robert W. Carey Awards for Performan...
Mathematics and Materials Science Research Take Top Prize at Nation's Premier High School Science Competition
PASADENA, Calif., Nov. 21 /PRNewswire/ -- Research projects in the areas of Mathematics and Materials Science scored the highest marks this evening, as Lynnelle Ye of Palo Alto, California and the team of Ryan Lindeborg of Laguna Niguel, California and Andrew James Swoboda of Oakton...
VA Maryland Health Care System Recognized with an EPA Trailblazer Award
VA Maryland Health Care System Among Six Maryland Hospitals Awarded with EPA Trailblazer Awards/I/P
PBaltimore, Md. (Vocus) November 21, 2009 -- The U.S. Environmental Protection Agency (EPA) presented six Maryland hospitals with Trailblazer Awards for their environmental leadership at ...
Patient Files Suit Against St. Vincent's Hospital in New York City as a Result of the Alleged Use by the Hospital of an HIV Infected Device During a Routine Procedure
NEW YORK, Nov. 21 /PRNewswire/ -- Milvia Lopez, by her attorney MICHAEL STEWART FRANKEL, of New York City, recently filed suit, in Supreme Court, New York County, bearing Index # 112888/2009. The complaint alleges that while Ms. Lopez underwent a routine transesophageal echocardiogram (&quo...
|
|
|
|
|
|
|
|
|
